The DOI matches its Crossref record; 104 of the 104 references it cites were found in a registry or an index.
Romidepsin: a new therapy for cutaneous T-cell lymphoma and a potential therapy for solid tumors
Open accessAbstract
Romidepsin is a histone deacetylase inhibitor (HDI), approved by the US FDA for the treatment of cutaneous T-cell lymphoma (CTCL). Although various mechanisms have been proposed for the activity of HDIs, including induction of genes controlling cell cycle, acetylation of cytoplasmic proteins and direct induction of apoptosis, the mechanism underlying activity of romidepsin and other HDIs in CTCL is not known. Romidepsin induces long-lasting responses. The side-effect profile is similar to that of other HDIs, causing fatigue, nausea and thrombocytopenia. Management of the CTCL population requires vigilence to prevent infection with skin contaminants, and monitoring of potassium and magnesium, electrolytes found to be low in a large proportion of patients. Electrocardiographic (ECG) changes are common but are not associated with myocardial damage. When molecular end points were evaluated in 61 patients enrolled on a Phase II trial with romidepsin, response was associated with persistence of acetylated histone H3, suggesting that drug exposure is important in effective therapy with romidepsin. Future studies will endeavor to identify combination strategies to increase the efficacy both in resistant CTCL and in solid tumors and to identify biomarkers of response that will allow selection of patients most likely to benefit from the therapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Anticancer activities of histone deacetylase inhibitors
Bolden, J. E., Peart, M. J., & Johnstone, R. W. (2006) · Nature Reviews Drug Discovery · doi:10.1038/nrd2133 · Cited by 2,919
Histone Deacetylase Inhibitors: Overview and Perspectives
Dokmanovic, M., Clarke, C., & Marks, P. A. (2007) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-0324 · Cited by 1,164
Duvic, M., Talpur, R., Ni, X., Zhang, C., Hazarika, P., Kelly, C., Chiao, J. H., Reilly, J. F., Ricker, J. L., Richon, V. M., et al. (2007) · Blood · doi:10.1182/blood-2006-06-025999 · Cited by 1,141
Richon, V. M., Sandhoff, T. W., Rifkind, R. A., & Marks, P. A. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.180316197 · Cited by 1,090
Olsen, E. A., Kim, Y. H., Kuzel, T. M., Pacheco, T. R., Foss, F. M., Parker, S., Frankel, S. R., Chen, C., Ricker, J. L., Arduino, J. M., et al. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.10.2434 · Cited by 1,055
Histone deacetylases and cancer
Glozak, M. A., & Seto, E. (2007) · Oncogene · doi:10.1038/sj.onc.1210610 · Cited by 1,031
Kelly, W. K., O'Connor, O. A., Krug, L. M., Chiao, J. H., Heaney, M., Curley, T., MacGregore-Cortelli, B., Tong, W., Secrist, J. P., Schwartz, L., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.14.167 · Cited by 905
Piekarz, R. L., Frye, R., Turner, M., Wright, J. J., Allen, S. L., Kirschbaum, M. H., Zain, J., Prince, H. M., Leonard, J. P., Geskin, L. J., et al. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2008.21.6150 · Cited by 740
Self-citation(2002) · PubMed · Cited by 732
Chemical phylogenetics of histone deacetylases
Bradner, J. E., West, N., Grachan, M. L., Greenberg, E. F., Haggarty, S. J., Warnow, T., & Mazitschek, R. (2010) · Nature Chemical Biology · doi:10.1038/nchembio.313 · Cited by 720
Acetylation of non-histone proteins modulates cellular signalling at multiple levels
Spange, S., Wagner, T., Heinzel, T., & Krämer, O. H. (2009) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/j.biocel.2008.08.027 · Cited by 664
Whittaker, S. J., Demierre, M.-F., Kim, E. J., Rook, A. H., Lerner, A., Duvic, M., Scarisbrick, J., Reddy, S., Robak, T., Becker, J. C., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2010.28.9066 · Cited by 664
Kelly, W. K., Richon, V. M., O’Connor, O. A., Curley, T., MacGregor‐Cortelli, B., Tong, W. P., Klang, M. G., Schwartz, L. B., Richardson, S., Rosa, E., et al. (2003) · PubMed · Cited by 624
Hideshima, T., Bradner, J. E., Wong, J., Chauhan, D., Richardson, P., Schreiber, S. L., & Anderson, K. C. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0503221102 · Cited by 593
Gui, C.-Y., Ngo, L., Xu, W. S., Richon, V. M., & Marks, P. A. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0307708100 · Cited by 550
Ungerstedt, J. S., Sowa, Y., Xu, W.-S., Shao, Y., Dokmanovic, M., Perez, G., Ngo, L., Holmgren, A., Jiang, X., & Marks, P. A. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0408732102 · Cited by 503
Sandor, V. A., Bakke, S., Robey, R. W., Kang, M. H., Blagosklonny, M. V., Bender, J., Brooks, R. A., Piekarz, R., Tucker, E. E., Figg, W. D., et al. (2002) · PubMed · Cited by 502
Self-citationUEDA, H., NAKAJIMA, H., HORI, Y., FUJITA, T., NISHIMURA, M., GOTO, T., & OKUHARA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.301 · Cited by 489
FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor
Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., & Horinouchi, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4027 · Cited by 487
(2003) · PubMed · Cited by 465
Garcia-Manero, G., Yang, H., Bueso-Ramos, C., Ferrajoli, A., Cortes, J., Wierda, W. G., Faderl, S., Koller, C., Morris, G., Rosner, G., et al. (2008) · Blood · doi:10.1182/blood-2007-06-098061 · Cited by 459
Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R., & Bates, S. E. (2001) · Blood · doi:10.1182/blood.v98.9.2865 · Cited by 445
Self-citationRyan, Q. C., Headlee, D., Acharya, M., Sparreboom, A., Trepel, J. B., Ye, J., Figg, W. D., Hwang, K., Chung, E. J., Murgo, A., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.02.188 · Cited by 411
Self-citationByrd, J. C. (2004) · Blood · doi:10.1182/blood-2004-05-1693 · Cited by 398
Modulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228
Yu, X. (2002) · CancerSpectrum Knowledge Environment · doi:10.1093/jnci/94.7.504 · Cited by 360
Clinical Studies of Histone Deacetylase Inhibitors
Prince, H. M., Bishton, M. J., & Harrison, S. J. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2785 · Cited by 356
Munshi, A., Kurland, J. F., Nishikawa, T., Tanaka, T., Hobbs, M. L., Tucker, S. L., Ismail, S., Stevens, C., & Meyn, R. E. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2088 · Cited by 345
Lee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T., & Bates, S. E. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09793-7 · Cited by 336
Self-citationCatley, L., Weisberg, E., Kiziltepe, T., Tai, Y.-T., Hideshima, T., Neri, P., Tassone, P., Atadja, P., Chauhan, D., Munshi, N. C., et al. (2006) · Blood · doi:10.1182/blood-2006-04-016055 · Cited by 336
Giles, F., Fischer, T., Cortes, J., Garcia-Manero, G., Beck, J., Ravandi, F., Masson, E., Rae, P., Laird, G., Sharma, S., et al. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-0511 · Cited by 312
Ellis, L., Pan, Y., Smyth, G. K., George, D. J., McCormack, C., Williams-Truax, R., Mita, M., Beck, J., Burris, H., Ryan, G., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4262 · Cited by 297
Sandor, V, Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M. V., & Bates, S. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1327 · Cited by 290
Self-citationGojo, I., Jiemjit, A., Trepel, J. B., Sparreboom, A., Figg, W. D., Rollins, S., Tidwell, M. L., Greer, J., Chung, E. J., Lee, M.-J., et al. (2007) · Blood · doi:10.1182/blood-2006-05-021873 · Cited by 281
Self-citationZhao, Y., Lu, S., Wu, L., Chai, G., Wang, H., Chen, Y., Sun, J., Yu, Y., Zhou, W., Zheng, Q., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.7.2782-2790.2006 · Cited by 277
UEDA, H., MANDA, T., MATSUMOTO, S., MUKUMOTO, S., NISHIGAKI, F., KAWAMURA, I., & SHIMOMURA, K. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.315 · Cited by 257
Dai, Y., Rahmani, M., Dent, P., & Grant, S. (2005) · Molecular and Cellular Biology · doi:10.1128/mcb.25.13.5429-5444.2005 · Cited by 245
Steele, N. L., Plumb, J. A., Vidal, L., Tjørnelund, J., Knoblauch, P., Rasmussen, A., Ooi, C. E., Buhl-Jensen, P., Brown, R., Evans, T. R. J., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1786 · Cited by 244
Shah, M. H., Binkley, P., Chan, K., Xiao, J., Arbogast, D., Collamore, M., Farra, Y., Young, D., & Grever, M. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2689 · Cited by 241
Piekarz, R. L., Frye, A. R., Wright, J. J., Steinberg, S. M., Liewehr, D. J., Rosing, D. R., Sachdev, V., Fojo, T., & Bates, S. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-2095 · Cited by 232
Self-citationBadros, A., Burger, A. M., Philip, S., Niesvizky, R., Kolla, S. S., Goloubeva, O., Harris, C., Zwiebel, J., Wright, J. J., Espinoza-Delgado, I., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2850 · Cited by 231
Rational Combinations Using HDAC Inhibitors
Bots, M., & Johnstone, R. W. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2786 · Cited by 217
Introducing a new entity: chemotherapy-induced arrhythmia
Guglin, M., Aljayeh, M., Saiyad, S., Ali, R., & Curtis, A. B. (2009) · Europace · doi:10.1093/europace/eup300 · Cited by 214
Camphausen, K., Burgan, W., Cerra, M., Oswald, K. A., Trepel, J. B., Lee, M.-J., & Tofilon, P. J. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2630 · Cited by 209
A phase I trial of Depsipeptide (FR901228) in patients with advanced cancer
Marshall, J. L., Rizvi, N., Kauh, J., Dahut, W., Figuera, M., Kang, M. H., Figg, W. D., Wainer, I., Chaissang, C., Zhaoyang Li, M., et al. (2002) · Journal of Experimental Therapeutics and Oncology · doi:10.1046/j.1359-4117.2002.01039.x · Cited by 204
Self-citationGuo, F., Sigua, C., Tao, J., Bali, P., George, P., Li, Y., Wittmann, S., Moscinski, L., Atadja, P., & Bhalla, K. (2004) · Cancer Research · doi:10.1158/0008-5472.can-03-2629 · Cited by 202
Piekarz, R. L., Robey, R. W., Zhan, Z., Kayastha, G., Sayah, A., Abdeldaim, A. H., Torrico, S., & Bates, S. E. (2004) · Blood · doi:10.1182/blood-2003-09-3068 · Cited by 186
Self-citationMolife, L. R., Attard, G., Fong, P. C., Karavasilis, V., Reid, A. H. M., Patterson, S., Riggs, C. E., Higano, C., Stadler, W. M., McCulloch, W., et al. (2010) · Annals of Oncology · doi:10.1093/annonc/mdp270 · Cited by 184
Regulation of the HIF-1α stability by histone deacetylases
Kim, S. H., Jeong, J.-W., Park, J. Y., Lee, J., Seo, J., Jung, B., Bae, M., & Kim, K. (2007) · Oncology Reports · doi:10.3892/or.17.3.647 · Cited by 170
Kitazono, M. (2001) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.86.7.3430 · Cited by 163
Geng, L., Cuneo, K. C., Fu, A., Tu, T., Atadja, P. W., & Hallahan, D. E. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0049 · Cited by 163
Inhibition of Histone Deacetylation: A Strategy for Tumor Radiosensitization
Camphausen, K., & Tofilon, P. J. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2007.11.6202 · Cited by 162
Weiser, T. S., Guo, Z. S., Ohnmacht, G. A., Parkhurst, M. L., Tong-On, P., Marincola, F. M., Fischette, M. R., Yu, X., Chen, G. A., Hong, J. A., et al. (2001) · Journal of Immunotherapy · doi:10.1097/00002371-200103000-00010 · Cited by 162
Ramalingam, S. S., Belani, C. P., Ruel, C., Frankel, P., Gitlitz, B., Koczywas, M., Espinoza-Delgado, I., & Gandara, D. (2009) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e318191520c · Cited by 159
Medicinal importance of grapefruit juice and its interaction with various drugs
Kiani, J. G., & Imam, S. Z. (2007) · Nutrition Journal · doi:10.1186/1475-2891-6-33 · Cited by 158
Schrump, D. S. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2787 · Cited by 153
A Phase II Study of Depsipeptide in Refractory Metastatic Renal Cell Cancer
Stadler, W. M., Margolin, K. A., Ferber, S., McCulloch, W. F., & Thompson, J. A. (2006) · Clinical Genitourinary Cancer · doi:10.3816/cgc.2006.n.018 · Cited by 151
Epigenetic Modifiers: Basic Understanding and Clinical Development
Piekarz, R., & Bates, S. E. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2788 · Cited by 151
Self-citationUeda, H., Nakajima, H., Hori, Y., Goto, T., & OKUHARA, M. (1994) · Bioscience Biotechnology and Biochemistry · doi:10.1271/bbb.58.1579 · Cited by 144
Kummar, S., Gutierrez, M. E., Gardner, E. R., Donovan, E. A., Hwang, K., Chung, E. J., Lee, M.-J., Maynard, K., Kalnitskiy, M., Chen, A. P., et al. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0791 · Cited by 140
Self-citationEdwards, A., Li, J., Atadja, P. W., Bhalla, K. N., & Haura, E. B. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0761 · Cited by 134
Zhang, Y., Jung, M., Dritschilo, A., & Jung, M. (2004) · Radiation Research · doi:10.1667/rr3192 · Cited by 134
Klimek, V. M., Fircanis, S., Maslak, P. G., Guernah, I., Baum, M., Wu, N. F., Panageas, K. S., Wright, J. J., Pandolfi, P. P., & Nimer, S. D. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0318 · Cited by 130
Joseph, J., Mudduluru, G., Antony, S., Vashistha, S., Ajitkumar, P., & Somasundaram, K. (2004) · Oncogene · doi:10.1038/sj.onc.1207852 · Cited by 127
Clinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0135 · Cited by 126
Self-citationBono, J. S. D., Kristeleit, R. S., Tolcher, A. W., Fong, P. C. C., Pacey, S., Karavasilis, V., Mita, M. M., Shaw, H. M., Workman, P., Kaye, S. B., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-0376 · Cited by 126
Rosato, R. R., Almenara, J. A., Maggio, S. C., Coe, S., Atadja, P. W., Dent, P., & Grant, S. (2008) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0385 · Cited by 124
ROBBINS, A. R., Jablonski, S. A., Yen, T. J., Yoda, K., Robey, R. W., Bates, S. E., & Sackett, D. L. (2005) · Cell Cycle · doi:10.4161/cc.4.5.1690 · Cited by 105
Self-citationLee, J., Park, J., Jung, Y., Kim, J.-H., Jong, H.-S., Kim, T., & Bang, Y. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0419 · Cited by 103
Galli, M., Salmoiraghi, S., Golay, J., Gozzini, A., Crippa, C., Pescosta, N., & Rambaldi, A. (2009) · Annals of Hematology · doi:10.1007/s00277-009-0793-8 · Cited by 101
Robey, R. W., Zhan, Z., Piekarz, R., Kayastha, G., Fojo, T., & Bates, S. E. (2006) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-05-1423 · Cited by 99
Self-citationClinical and Molecular Responses in Lung Cancer Patients Receiving Romidepsin
Schrump, D. S., Fischette, M. R., Nguyen, D. M., Zhao, M., Li, X., Kunst, T. F., Hancox, A., Hong, J. A., Chen, G. A., Kruchin, E., et al. (2007) · Clinical Lung Cancer · doi:10.1016/s1525-7304(11)70818-x · Cited by 97
Self-citationAssessing proarrhythmic potential of drugs when optimal studies are infeasible
Rock, E. P., Finkle, J. K., Fingert, H. J., Booth, B. P., Garnett, C. E., Grant, S. N., Justice, R. L., Kovacs, R. J., Kowey, P. R., Rodríguez, I., et al. (2009) · American Heart Journal · doi:10.1016/j.ahj.2009.02.020 · Cited by 85
Nishioka, C., Ikezoe, T., Yang, J., Takeuchi, S., Koeffler, H. P., & Yokoyama, A. (2008) · Leukemia Research · doi:10.1016/j.leukres.2008.02.018 · Cited by 82
Glucose Metabolism as a Target of Histone Deacetylase Inhibitors
Wardell, S. E., Ilkayeva, O., Wieman, H. L., Frigo, D. E., Rathmell, J. C., Newgard, C. B., & McDonnell, D. P. (2008) · Molecular Endocrinology · doi:10.1210/me.2008-0179 · Cited by 82
Fouladi, M., Furman, W. L., Chin, T. K., Freeman, B. B., Dudkin, L., Stewart, C. F., Krailo, M., Speights, R., Ingle, A. M., Houghton, P. J., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.4964 · Cited by 82
Whitehead, R. P., Rankin, C. J., Hoff, P. M., Gold, P. J., Billingsley, K. G., Chapman, R., Wong, L., Ward, J. H., Abbruzzese, J. L., & Blanke, C. D. (2008) · Investigational New Drugs · doi:10.1007/s10637-008-9190-8 · Cited by 80
Induction of MAGE-3 expression in lung and esophageal cancer cells
Weiser, T. S., Ohnmacht, G. A., Guo, Z. S., Fischette, M. R., Chen, G. A., Hong, J. A., Nguyen, D. M., & Schrump, D. S. (2001) · The Annals of Thoracic Surgery · doi:10.1016/s0003-4975(00)02421-8 · Cited by 80
Laboratory correlates for a phase II trial of romidepsin in cutaneous and peripheral T‐cell lymphoma
Bates, S. E., Zhan, Z., Steadman, K., Obrzut, T., Luchenko, V. L., Frye, R., Robey, R. W., Turner, M. L. C., Gardner, E. R., Figg, W. D., et al. (2009) · British Journal of Haematology · doi:10.1111/j.1365-2141.2009.07954.x · Cited by 76
Self-citationEdelstein, L. C., Micheva-Viteva, S., Phelan, B. D., & Dougherty, J. P. (2009) · AIDS Research and Human Retroviruses · doi:10.1089/aid.2008.0294 · Cited by 74
Woo, S., Gardner, E. R., Chen, X., Ockers, S. B., Baum, C. E., Sissung, T. M., Price, D. K., Frye, R., Piekarz, R., Bates, S. E., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1215 · Cited by 71
Self-citationRitchie, D., Piekarz, R., Blombery, P. A., Karai, L., Pittaluga, S., Jaffe, E. S., Raffeld, M. A., Janik, J. E., Prince, H. M., & Bates, S. E. (2009) · Haematologica · doi:10.3324/haematol.2009.008607 · Cited by 67
Self-citationPohlman, B. L., Advani, R. H., Duvic, M. A., Hymes, K. B., Intragumtornchai, T., Lekhakula, A., Shpilberg, O., Lerner, A., Ben‐Yehuda, D., Beylot-Barry, M., et al. (2009) · Blood · doi:10.1182/blood.v114.22.920.920 · Cited by 66
Martirosyan, A., Leonard, S. S., Shi, X., Griffith, B. N., Gannett, P. M., & Strobl, J. S. (2006) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.096891 · Cited by 65
Odenike, O. M., Alkan, S., Sher, D., Godwin, J. E., Huo, D., Brandt, S. J., Green, M., Xie, J., Zhang, Y., Vesole, D. H., et al. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1007 · Cited by 65
Shiozawa, K., Nakanishi, T., Tan, M., Fang, H.-B., Wang, W.-C., Edelman, M. J., Carlton, D., Gojo, I., Sausville, E. A., & Ross, D. D. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-1587 · Cited by 64
FK228 inhibits Hsp90 chaperone function in K562 cells via hyperacetylation of Hsp70
Wang, Y., Wang, S., Zhang, X., Zhao, M., Hou, C., Xu, Y.-J., Du, Z., & Yu, X. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2007.03.076 · Cited by 59
Inoue, H., Shiraki, K., Ohmori, S., Sakai, T., Deguchi, M., Yamanaka, T., Okano, H., & Nakano, T. (2002) · International Journal of Molecular Medicine · doi:10.3892/ijmm.9.5.521 · Cited by 54
HDAC Inhibitors and Cardiac Safety
Molife, R., Fong, P. C. C., Scurr, M. R., Judson, I. R., Kaye, S. B., & Bono, J. S. D. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-06-1715 · Cited by 52
Steiner, F. A., Hong, J. A., Fischette, M. R., Beer, D. G., Guo, Z. S., Chen, G. A., Weiser, T. S., Kassis, E. S., Nguyen, D. M., Lee, S., et al. (2005) · Oncogene · doi:10.1038/sj.onc.1208376 · Cited by 52
Chen, J., Zhang, M., Ju, W., & Waldmann, T. A. (2009) · Blood · doi:10.1182/blood-2008-04-149658 · Cited by 49
Kano, Y., Akutsu, M., Tsunoda, S., Izumi, T., Kobayashi, H., Mano, H., & Furukawa, Y. (2006) · Investigational New Drugs · doi:10.1007/s10637-006-9000-0 · Cited by 48
Dong, G., Wang, L., Wang, C., Yang, T., Kumar, M. V., & Dong, Z. (2008) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.108.137398 · Cited by 44
Zhang, L., Lebwohl, D., Masson, E., Laird, G., Cooper, M. R., & Prince, H. M. (2008) · Journal of Clinical Oncology · doi:10.1200/jco.2007.14.7249 · Cited by 43
Piekarz, R., Wright, J., Frye, R., Allen, S. L., Craig, M., Geskin, L. J., Hutchins, L. F., Joske, D. J. L., Kirschbaum, M. H., Leonard, J. P., et al. (2008) · Blood · doi:10.1182/blood.v112.11.1567.1567 · Cited by 40
Self-citationBishton, M. J., Kenealy, M. K., Johnstone, R. W., Rasheed, W. K., & Prince, H. M. (2007) · Expert Review of Anticancer Therapy · doi:10.1586/14737140.7.10.1439 · Cited by 39
Shiraga, T., Tozuka, Z., Ishimura, R., Kawamura, A., & Kagayama, A. (2005) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.28.124 · Cited by 38
Weber, D. M., Jagannath, S., Mazumder, A., et al. (2007) · Blood · doi:10.1182/blood.v110.11.1172.1172 · Cited by 33
Harrison, S. J., Quach, H., Yuen, K., et al. (2008) · Blood · doi:10.1182/blood.v112.11.3698.3698 · Cited by 33
Kanji, Z., & Jung, K. (2009) · Intensive and Critical Care Nursing · doi:10.1016/j.iccn.2009.03.004 · Cited by 30
Cardiovascular toxicity of molecularly targeted agents
Strevel, E. L., & Siu, L. L. (2009) · European Journal of Cancer · doi:10.1016/s0959-8049(09)70046-2 · Cited by 25
Histone Deacetylase Inhibitors: Emerging Anticancer Therapeutic Agents?
Kristeleit, R. S., Fong, P. C. C., Aherne, G. W., & Bono, J. S. D. (2005) · Clinical Lung Cancer · doi:10.3816/clc.2005.s.004 · Cited by 24
Fischer, T. H., Patnaik, A., Bhalla, K. N., Beck, J., Morganroth, J., Laird, G., Sharma, S., Scott, J. W., Dugan, M. H., & Giles, F. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.23.16_suppl.3106 · Cited by 23
Bremers, A. J. A., Andreola, S. A., Leo, E., Gallino, G., Rini, F., Lombardo, C., Belli, F., Kuppen, P. J. K., Parmiani, G., & Castelli, C. (2000) · International Journal of Cancer · doi:10.1002/1097-0215(20001215)88:6<992::aid-ijc24>3.0.co;2-9 · Cited by 22
Final results of a phase I study of oral belinostat (PXD101) in patients with solid tumors
Kelly, W. K., DeBono, J., Blumenschein, G., Lassen, U., Zain, J. M., O’Connor, O., Foss, F. M., Tjørnelund, J., Fagerberg, J., & Petrylak, D. P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.3531 · Cited by 10
Cited by
Role of Glutathione in Cancer: From Mechanisms to Therapies
Kennedy, L., Sandhu, J. K., Harper, M.-E., & Cuperlovic-Culf, M. (2020) · Biomolecules · doi:10.3390/biom10101429 · Cited by 880
Tumor suppressor p53: Biology, signaling pathways, and therapeutic targeting
Hernández Borrero, L. J., & El-Deiry, W. S. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188556 · Cited by 748
Suraweera, A., O’Byrne, K. J., & Richard, D. J. (2018) · Frontiers in Oncology · doi:10.3389/fonc.2018.00092 · Cited by 669
Nepali, K., Sharma, S., Sharma, M., Bedi, P. M. S., & Dhar, K. L. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.03.018 · Cited by 435
Oxidative Cyclization in Natural Product Biosynthesis
Tang, M.-C., Zou, Y., Watanabe, K., Walsh, C. T., & Tang, Y. (2017) · Chemical Reviews · doi:10.1021/acs.chemrev.6b00478 · Cited by 425
Metadata
- Authors
- Grant, C., Rahman, F., Piekarz, R., Peer, C., Frye, R., Robey, R. W., Gardner, E. R., Figg, W. D., & Bates, S. E.
- Venue
- Expert Review of Anticancer Therapy
- Publisher
- Informa UK Limited
- Published
- 2010-07
- Volume
- 10
- Issue
- 7
- Pages
- 997-1008
- ISSN
- 1473-7140 (ISSN-L)
- 1744-8328
- OpenAlex
- W2051257692
- Cited by
- 291
- References
- 104
- FWCI
- 6.85
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.